Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 14/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.45 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.45 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.45 |
| ▸ | KDM6B | O15054 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | KDM4A | O75164 | 2/20 | 0.43 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.43 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6370629 | 0.86 | PLK1 (0.46) | KDM4CTBXA2RPTGER3PTGER2PTGDR | |
| SCHEMBL6269745 | 0.85 | KDM4E (0.48) | TBXA2RPTGER3PTGER2PTGDRKDM4E | |
| SCHEMBL4951259 | 0.82 | KDM4C (0.56) | KDM4CKDM6BKDM4EKDM4AKDM4D | |
| SCHEMBL22189609 | 0.81 | KDM4C (0.45) | KDM4CKDM6BKDM4EKDM4AKDM4D | |
| SCHEMBL29581046 | 0.81 | KDM4C (0.45) | KDM4CKDM6BKDM4EKDM4AKDM4D | |
| SCHEMBL6370115 | 0.78 | FTO (0.47) | TBXA2RPTGER3PTGER2PTGDRKDM6B | |
| SCHEMBL30100781 | 0.74 | KDM4C (0.56) | KDM4CKDM6BKDM4EKDM4AKDM4D | |
| SCHEMBL115648 | 0.74 | KDM4C (0.56) | KDM4CKDM6BKDM4EKDM4AKDM4D | |
| SCHEMBL6365203 | 0.74 | SLC6A4 (0.65) | MEN1KMT2AMAPTTSHRSLC6A2 | |
| SCHEMBL6364445 | 0.74 | SLC6A4 (0.65) | MEN1KMT2AMAPTTSHRSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556353-A1 | DIARYL COMPOUNDS AS MONOAMINE REUPTAKE INHIBITORS | Pfizer Limited (GB) | 2005-07-27 | — | — | EP | disclosed |
| US-20050026920-A1 | Selective serotonin re-uptake inhibitors; use in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder, substance abuse disorders and sexual dysfunction | PFIZER INC | 2005-02-03 | — | — | US | disclosed |
| US-6800652-B2 | SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS | PFIZER INC. | 2004-10-05 | — | — | US | disclosed |
| US-20040097509-A1 | Diaryl compounds | PFIZER INC. | 2004-05-20 | — | — | US | disclosed |
| WO-2004016593-A1 | DIARYL COMPOUNDS AS MONOAMINE REUPTAKE INHIBITORS | PFIZER LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097509-A1 | Diaryl compounds | CCNL2, CCNI, CCNA1 | KDM4C 2059/4885TBXA2R 3416/4885PTGER3 2239/4885 |
| US-20050026920-A1 | Selective serotonin re-uptake inhibitors; use in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder, substance abuse disorders and sexual dysfunction | SLC6A4, SLC6A2, SLC6A3 | KDM4C 4125/4885TBXA2R 1479/4885PTGER3 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.